MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an ...
OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...
The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results